Review Article

Redefining Hormone Sensitive Disease in Advanced Prostate Cancer

Table 1

Hormonal therapy in prostate cancer.

ClassExisting drugs Investigational drugs

EstrogenDiethylstilbestrol (DES)
GnRH agonistsGoserelin, leuprolide, triptorelin, histrelin acetate
GnRH antagonistsDegarelix, *abarelix
AntiandrogensBicalutamide, nilutamide, flutamide, **cyproterone acetateMDV3100, TOK-001
Non-specific,cytochrome P450 enzyme inhibitorsKetoconazole
Specific CYP17 inhibitorsAbiraterone acetateTAK-700, TOK-001
GlucocorticoidsPrednisone, Dexamethasone, others

*Abarelix use in the United States was previously limited to a registry program and it is not actively marketed in the United States currently.
**Cyproterone acetate is not currently FDA approved for the treatment of prostate cancer in the United States.